Piper Sandler Starts Quest Diagnostics (DGX) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $245.62 +1.26%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 18 | New: 18
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 18 | New: 18
Join SI Premium – FREE
Piper Sandler analyst David Westenberg initiates coverage on Quest Diagnostics (NYSE: DGX) with a Neutral rating and a price target of $145.00.
For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $141.92 yesterday.
You May Also Be Interested In
- Jefferies Starts National Stock Exchange of India (NSE:IN) at Buy
- Northland Starts Cavco Industries (CVCO) at Outperform
- JPMorgan Starts FANUC Corp (6954:JP) (FANUY) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
